Search for: "More v. Johnson" Results 1061 - 1080 of 5,582
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Jan 2022, 2:01 pm by John Elwood
Relisted cases — particularly newly relisted ones — are much more likely to be granted. [read post]
8 Jun 2023, 7:43 am by Ashwin Varma
Among the two most significant was a 2016 complaint by Pfizer alleging that claimed that Johnson & Johnson—the maker of Remicade, a best-selling medication for autoimmune disease—threatened not to pay rebates to PBMs unless they excluded from their formulary Pfizer’s biosimilar imitator to Remicade: Inflectra. [read post]
17 Feb 2018, 7:31 am
"...It is now - key takeaways Not as greasy as some takeaways,the IPKat boxes up the lessonsof L'Oreal v RN VenturesOn the patent side of the case, there are five key takeaways from Mr Justice Carr's decision: Construction has been rebranded as "interpretation", thus emphasizing its more flexible  role when we get to assessing equivalence under the new Actavis questions (or Lilly questions, depending on who you ask) (see… [read post]
3 Oct 2007, 1:45 pm
Which is way more than the four plaintiffs recovered at trial. [read post]
17 May 2012, 5:44 am
Johnson, 117 F.3d 1429, 1997 WL 381926 at *3 (10th Cir. 1997) (unpublished table decision). ... [read post]